EFFICIENCY OF ADJUVANT XELOX CHEMOTHERAPY FOR PATIENTS WITH RESECTABLE GASTRIC IN RUSSIA (SINGLE INSTITUTION RETROSPECTIVE STUDY)

Ivan Stilidi, Sergey Nered, Aleksey Kalinin, Olesya Rossomakhina, Anton Barchuk
2019 Voprosi onkologii  
Introduction. The effectiveness of the Asian regimen of adjuvant chemotherapy in patients with gastric cancer in the European population remains unclear. The aim of our study was a retrospective assessment of adjuvant chemotherapy (XELOX regimen) after radical surgery (R0) on overall survival. Methods. Database of pts with resectable gastric cancer with stage >pT3 and/or pN+ and M0, who were operated (R0) at single oncological institution during 2007-2017 was reviewed. In univariate and
more » ... variate and multivariate analyzes were included demographic characteristics, type of tumor according to Lauren, stage, type of treatment and others. Results. 396 pts were identified and 286 were available for analysis.106 (37%) pts received at least one cycle of adjuvant chemotherapy. In univariate analysis, 5OS rate was 64% [95% Cl, 52-80] и 56% [95% Cl, 48-64; p=0,21] in patients received adjuvant chemotherapy and only surgical treatment. After stratifying patients depending on the regional lymph nodes metastasis, 5OS rate in pts with pN1-3 was 69% [95% CI, 57-85] vs 47% [95% CI, 39-58; p = 0,01], respectively...
doi:10.37469/0507-3758-2019-65-2-256-262 fatcat:qgr6zqw5gvdabgjya3lzy3qhz4